X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NOVARTIS ALEMBIC PHARMA/
NOVARTIS
 
P/E (TTM) x 26.6 351.0 7.6% View Chart
P/BV x 6.1 17.3 35.1% View Chart
Dividend Yield % 0.8 1.7 46.5%  

Financials

 ALEMBIC PHARMA   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
NOVARTIS
Mar-16
ALEMBIC PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs792982 80.6%   
Low Rs443556 79.6%   
Sales per share (Unadj.) Rs167.0252.9 66.0%  
Earnings per share (Unadj.) Rs38.262.1 61.4%  
Cash flow per share (Unadj.) Rs42.063.3 66.3%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.61.3 49.8%  
Book value per share (Unadj.) Rs84.9363.6 23.3%  
Shares outstanding (eoy) m188.5231.96 589.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.0 121.5%   
Avg P/E ratio x16.212.4 130.7%  
P/CF ratio (eoy) x14.712.2 121.0%  
Price / Book Value ratio x7.32.1 343.8%  
Dividend payout %10.516.1 65.1%   
Avg Mkt Cap Rs m116,38324,580 473.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m4,2141,801 233.9%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m31,4878,083 389.5%  
Other income Rs m55829 6.6%   
Total revenues Rs m31,5428,913 353.9%   
Gross profit Rs m10,060234 4,295.4%  
Depreciation Rs m72237 1,967.6%   
Interest Rs m372 2,044.4%   
Profit before tax Rs m9,3561,025 912.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-217 -9.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m2,160752 287.3%   
Profit after tax Rs m7,1941,986 362.2%  
Gross profit margin %31.92.9 1,102.7%  
Effective tax rate %23.173.4 31.5%   
Net profit margin %22.824.6 93.0%  
BALANCE SHEET DATA
Current assets Rs m15,06612,678 118.8%   
Current liabilities Rs m7,6742,433 315.4%   
Net working cap to sales %23.5126.7 18.5%  
Current ratio x2.05.2 37.7%  
Inventory Days Days6733 204.8%  
Debtors Days Days4122 180.7%  
Net fixed assets Rs m8,23769 11,903.8%   
Share capital Rs m377160 235.9%   
"Free" reserves Rs m15,41611,460 134.5%   
Net worth Rs m16,00511,621 137.7%   
Long term debt Rs m00-   
Total assets Rs m24,59414,400 170.8%  
Interest coverage x255.2570.5 44.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.6 228.1%   
Return on assets %29.413.8 213.0%  
Return on equity %44.917.1 263.0%  
Return on capital %58.723.6 248.9%  
Exports to sales %55.70.7 7,484.3%   
Imports to sales %10.418.6 56.1%   
Exports (fob) Rs m17,55160 29,154.2%   
Imports (cif) Rs m3,2831,503 218.5%   
Fx inflow Rs m17,811186 9,560.1%   
Fx outflow Rs m5,3181,821 292.1%   
Net fx Rs m12,493-1,635 -764.3%   
CASH FLOW
From Operations Rs m9,3042,531 367.6%  
From Investments Rs m-3,105-8,270 37.5%  
From Financial Activity Rs m-1,959-386 507.9%  
Net Cashflow Rs m4,240-6,125 -69.2%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 2.0 145.0%  
FIIs % 9.1 1.6 568.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.5 64.7%  
Shareholders   49,328 41,647 118.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - WYETH LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS